Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Research: Forums: Live Discussions
Live Discussion Transcript


Posted 6 September 2006

E-mail discussion
Printable version

Live Discussion: Alzheimer Presenilins in the Nuclear Membrane, Interphase Kinetochores, and Centrosomes Suggest a Role in Chromosome Segregation

Return to Discussion Text

Live discussion held 20 March 1998.

Participants: Jinhe Li, Huntington Potter, Marc Paradis, June Kinoshita, Oksana Berezovska, Chris Weihl, MQ Xia.

Note: Transcript has been edited for clarity and accuracy.


Marc Paradis: Hello Jli and June.

June Kinoshita: Hi Marc!

Jli: Hi Marc!

June Kinoshita: Jinhe, where are you these days?

Jli: Hi June! I'm with Pharmacia & Upjohn since Jan.

Marc Paradis: Hello Hunt.

June Kinoshita: Hi Hunt!

Hpotter: Hi folks. Jinhe and I are on the phone together, so I may do the answering for both of us.

June Kinoshita: That's real multimedia! Hello Chris and Oksana.

Cweihl: Hi June. Am I late?

June Kinoshita: No. We haven't begun yet. Glad to see you Oksana. Why don't we begin. Anyone want to lob the first question?

Jli: I'm ready.

Marc Paradis: I'm ready as well

Cweihl: Me too.

Jli: Ready to take the bullets.

Marc Paradis: I would like to start by thanking June for giving me the opportunity to review and also to thank Hunt and Jinhe for writing an excellent paper that was fun to read and think about.

Hpotter: You did a great job.

June Kinoshita: I would like to thank Marc for the wonderful job he did.

Marc Paradis: I would just start with a question from my review if that is alright?

Hpotter: Sure.

Marc Paradis: One of the most interesting questions, I thought, concerned your mechanisms for non-disjunction in post-mitotic neurons and how this might cause AD. I would like to hear more of your thoughts on this.

Hpotter: We don't actually know how many neurons are totally post-mitotic. As we mentioned in our formal response, there is a fairly large number of new neurons generated in the dentate. However, if we accept the premise that neurons are normally post-mitotic, we have to explain why there are so many mitotic markers in AD neurons.

Jli: So, 1-neurons have the potential to divide, 2-there are non-neuronal cells undergoing cell division, 3-the effect may occur during early development in all cells including those in brain.

Cweihl: Dr. Potter, I was interested if there is any precedent for a multi-transmembrane protein associating with chromosomes? And serve a role in mitosis?

Marc Paradis: Perhaps a very simple question, but I have never heard of this neuronal replacement before. Are there supposedly stem cells that generate the new neurons or do neurons actually make a decision to perform one division at some point in life?

Hpotter: I don't think that is known. Apparently the new neurons just appear in the midst of the old ones. It is not as though there were a region where all the stems cells are and then they migrate as in other regions.

June Kinoshita: I believe there are significant numbers of stem cells in adult brain.

Marc Paradis: If a structure like the dentate can turn over every 6 years, but is only allowed one turnover (because each cell only divides once) what happens after one complete turnover?

Hpotter: I did not mean to imply that each cell would turn over only once. It could turn over many times during the course of a life. But for the sake of the calculation I assumed one turnover per cell. If some cells turned over more than once in a given time and others not at all, then it might take more than 6 years for the entire dentate to turn over.

June Kinoshita: Have you been able to look at the number of trisomic neurons in the dentate across different age groups?

Hpotter: I have a question for discussion. What do you folks think of the idea that all of the effects of the APP and presenilin mutations on Aβ production are mediated through their effects on apoptosis?

Marc Paradis: I would say that it can't simply be apoptosis, because many stimuli and insults result in apoptosis, but only APP and PS mutations seem to cause AD (ignoring sporadic issues for the moment).

Hpotter: What I mean is that since apoptosis induced by normal means causes increases in Aβ, then maybe it is the apoptosis that the APP and PS mutants induce that leads to the increase in Aβ1-42.

June Kinoshita tells Oksana I'm curious what you might be observing with respect to presenilin localization....

Hpotter: Marc has a good point.

Jli: To Cweihl's Q: after looking at so many stainings for a long time, I think PSs are associated with some kind of cytoskeleton protein. And centrosome is the center of the organization of cytoskeleton protein. So they seem to have a chance to get together. But I don't know how, especially for a 7-tm protein.

Oksana: In mouse and human tissue we occasionally see the PS1 in nuclei, but it is also localized in the cytoplasm in cell body and processes.

Marc Paradis: The real test would be other neurologic diseases which cause apoptosis but do not cause AD or AD like symptoms.

Hpotter: June: we have tried to use fluorescence in situ hybridization to look at brain sections for trisomy 21. The problem is that the lipofuscin is so strongly fluorescent in aged brain that it obscures the hybridization spots. We will have to try other techniques.

Marc Paradis: I agree that Cweihl's question is a good one although not impossible given ER and Golgi localization.

Marc Paradis: Sorry, maybe also nuclear membrane localization too!

Cweihl: In your experiments involving interactions with other proteins. (2 hybrid) what regions of PS are you interested in?

Hpotter: To cweihl: Yes we see cytoplasmic staining in sections of brain tissue too. We discuss this a bit in the formal response. Probably different cells use the presenilins for different things. That might make a neuron that hopes not to divide use the PS proteins for some other membrane-cytoskeleton interactive function such as vesicle transport. Good point about other apoptosis diseases. One possibility is that they do cause some Aβ deposition, as does head trauma, but that if the apoptosis is transient, so will be the Aβ deposits.

Cweihl: To me the most compelling evidence of PS and apoptosis is the antiapoptotic nature of ALG-3.

June Kinoshita: It's been speculated that apoptosis is involved in all kinds of neurological diseases: ALS, Huntingtons, etc. How convincing is the evidence? I guess I should ask that about Alzheimer's too.

Hpotter: Cweihl: Absolutely. Also PS mutants cause apoptosis as do APP mutants.

Jli: Maybe apoptosis is not a process specific for any disease, but rather one of the final steps in many diseases.

Marc Paradis: I would tend to agree with Jli, simply by Occam's razor type arguments.

Cweihl: As far as PS. It appears to play a real role in apoptosis with caspase cleavage etc. Whereas APP mutants may just add to the overall sickness of the neurons.

Hpotter: June: Apoptosis is hard to be sure about in post-mortem brain because of all the insults that have occurred before you get the tissue. Also some of the techniques for measuring apoptosis are so sensitive that you can easily get false positive results.

Oksana: Hi, this is MQ Xia from Brad Hyman's lab, I just jump in the middle of this discussion. We have observed both nuclear staining and cytoplasmic staining of PS-1 in mouse and in human brains using polyclonal antibodies against the N-terminal of PS-1. In human brain, a lot of nuclear staining was observed, particularly granule cells of dentate gyrus. The nuclear staining appears to be related to postmortem interval. This paper is coming out very soon in Journal of Neurological Sciences.

June Kinoshita: Very interesting, MQ!

Marc Paradis: So perhaps PS1 is moved to the nucleus with apoptosis/cell death/post-mortem interval.

Cweihl: I am confused. What is post mortem interval?

Hpotter: Has anyone else used commercial antibodies (as we have, with an antibody from SANTA CRUZ ) We found the same nuclear membrane staining in the fibroblasts.

Marc Paradis: Such movement would be analogous to localization of steroid receptors to the nucleus on binding to steroids. This was actually a possibility that came to mind while reading Jli and

Hpotter's paper, but that I didn't have the space to get into in my review. BTW I would also be interested to hear about commercial antibodies.

Hpotter: PMI is the time from death to the time the autopsy is complete and you can get the brain. You can imagine what your tissue culture cells would look like if you left them with no oxygen or glucose for a few hours--lots of death.

Oksana: Postmortem interval is the time after death and before the brain was fixed. The same phenomenon was also observed in mouse brains of different postmortem interval. In human, after 12 hrs, PS-1 nuclear staining gets really weak -- sometimes cannot be seen at all.

Marc Paradis: Throwing out ideas here, perhaps the nuclear localization is related to the caspase cleavage and thereby to cell death/apoptosis?!

Cweihl: I have used Chemicon's rat monoclonal on western blots and Immunohistochem, and it works well.

June Kinoshita: Oh, so PS1 staining gets WEAKER with increased PS1.

Marc Paradis: Sorry, looks like I may have the sequence backwards here, agree with June?

Jli: I'm really happy to hear that from MQ Xia.

Oksana: Sorry , that I forgot to mention that our PS-1 antibody is a rabbit polyclonal to N-terminal 81 amino acid, similar to Dr. Potter's.

Hpotter: Actually the antibody was.

Oksana: MQ Xia: usually in human brain, after 12 hr PMI, nuclear staining gets weaker or invisible. This was most obviously observed in granule cells of dentate gyrus.

Marc Paradis: So I did have it backwards.

June Kinoshita: Are you suggesting others may have missed seeing the nuclear staining because the PMI was too long?

Oksana: MQXia. Very likely, and the antibody we used was by far the strongest. We seem to prefer polyclonal antibody against longer peptide.

Cweihl: Nuclear staining is far different from kinetechore localization during mitosis.

Hpotter: That is fascinating. We were happy to see the association with notch and PS expression during development since that would fit with a joint function in cell cycle regulation. Indeed several components of the notch signaling pathway have been shown be involved in cell cycle and in chromosome segregation.

Marc Paradis: The rapid disappearance post-mortem could be explained by rapid cleavage and processing of the PS, which is consistent with a lot of previous work.

June Kinoshita: For Hunt and Jinhe: Did Bruce McEwen's paper indicate whether granule cells were undergoing division more than other types?

Hpotter: J: He only could see it there for technical reasons.

June Kinoshita: So is it still an open question whether there is neurogenesis going on in adult animals in other regions of the brain?

Oksana: About PS1/notch colocalization. We have data that they do colocalize both temporally and, anatomically (in the same brain areas) and in the same neurons. It was double fluorescence.

Hpotter: The cleavage of PS proteins does seem to be related to some mistreatment of the cells. When we harvest, we put the cells directly into lysis/sample buffer with SDS and see full length protein. Others may trypsinize or harvest by centrifugation that would stress the cells. Maybe that is why so many see only the cleaved forms.

Jli: to Xia: Very interesting. Is it coming out soon?

Hpotter: Also Dewji and Singer said that full cleaved PS was only present when the cells were harvested carelessly: PNAS a few months ago.

Cweihl: Hunt, is the full length that you see from cell overexpressed or endogenous PS

Hpotter: Both.

Oksana: Xia: yes, it is in press, if not this month then next month will be likely.

Hpotter: What journal?

Oksana: xia: J. Neurological Sciences.

Cweihl: So Hunt do you believe in the cleavage of PS1?

Hpotter: Actually. we think it possible that the cleavage is a part of the normal function of the presenilins. If the proteins function as kinetochore receptors, they need to let go every time the cell enters enaphase. What better way than to be cleaved and stop functioning.

Jli: PS1/2 may be cleaved, but not necessarily completely for their function.

Marc Paradis: That's great stuff Hunt! What kind of cells are you looking at?

Hpotter: Full length in fibroblasts and transfected cos cells, and also fragments.

Cweihl: Do you see the cleavage products at all or just full length?

Jli: using both anti-flag and anti-ps abs.

June Kinoshita: If you speculate that AD pathology is seen early in hippocampus because of cell division there, how do you account for the spread to other brain. regions? Do you think there is cell division also going on at a slower rate, or is there some other mechanism by which dysfunction and death are spreading?

Hpotter: Actually, we are much more inclined to though think that the regional specificity reflects an astrocyte-microglial cell difference coupled to a difference in neuronal cell vulnerability. Both astrocytes and microglia divide throughout adulthood, and we know they are weird in Down syndrome. They could be the most affected by PS mutations causing problems with the cell cycle.

Jli: to June: different brain regions or cell types may have different extent of vulnerability to the aβ toxicity. That’s why only some of the regions are affected in AD.

June Kinoshita: In what ways are astrocytes and microglia weird in Down's?

Hpotter: One thing is clear. The cerebellum has amorphous amyloid but not mature amyloid. It also has no expression of the amyloid promoting factor ACT and almost no expression of the ACT and inflammation-inducing cytokine IL-1.

Marc Paradis: Hello again, Mqxia.

June Kinoshita: Welcome back MQ. You're not in drag anymore!

Hpotter: Astrocytes and microglia are spontaneously activated even in fetal brain There are 30 times as many IL-1-positive microglia in DS brain of all ages (Griffin et al , 1989).

Mqxia: Hi, nice to be back here.

June Kinoshita: Didn't know that. So inflammation may be important in Down's too?

Marc Paradis: Inflammation, I think, plays a role analogous to apoptosis, a final common pathway, not necessarily specific to AD. Of course, this doesn't negate the importance of studying or designing treatments based on inflammation or apoptosis. It just means that you probably won't cure AD that way, just slow it down.

Hpotter: Yes, inflammation (which we define in the brain as activated microglia and astrocytes and induced expression of inflammation proteins such as ACT and IL-1) is apparently constitutively activated in DS brain. I would expect that anti-inflammatory drugs would help them [Down syndrome individuals] develop better.

June Kinoshita: Interesting. I wonder if anyone is studying that possibility.

Jli: Very good point.

Marc Paradis: Hunt, you should start epidemiological studies of DS mothers with arthritis or some other condition for which they chronically take anti-inflammatories. Their DS children would be expected to have better outcomes... By DS mothers, I mean mothers of children with DS.

Hpotter: The only thing is that the inflammation is clearly responsible for expressing ACT and apoE, which appear to be necessary to get Aβ to polymerize efficiently. We have shown this in vitro, but Steve Paul's group at Lilly has shown it for ApoE in vivo.

Hpotter: I agree. That would be a good experiment. No one is trying I don't think.

Marc Paradis: Well, I'd be happy to help get that experiment going in any way that I can.

Hpotter: Lets talk. Maybe a drug company would help.

Jli: Let's try it.

June Kinoshita: It's a few minutes past 3PM, so I would like to release Hunt and Jinhe of their obligation to stay on line. Of course, everyone is free to continue chatting here. I want to thank Hunt and Jinhe for being here, and Marc for the wonderful discussion text. Our next live journal club is next Thursday, 4-5PM EST, with Rachael Neve, Nick Robakis and Dennis Selkoe. Should be another lively event!

Jli: Thanks to June and Marc.

Marc Paradis: I would like to say my thanks as well to Hunt, Jinhe and June. As well as to everyone who participated today. I learned quite a bit.

June Kinoshita: So did I.

Hpotter: Great. See you all next week at the next roast.

June Kinoshita: I'll say farewell for now. Off to lunch (I'm in California). Thanks again!

Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad